Development of Ac-225 Radiopharmaceuticals: TRIUMF Perspectives and Experiences

Background: The development of radiopharmaceuticals containing Ac-225 for targeted alpha therapy is an active area of academic and commercial research worldwide. Objectives: Despite promising results from recent clinical trials, Ac-225-radiopharmaceutical development still faces significant challenges that must be overcome to realize the widespread clinical use of Ac-225. Some of these challenges include the limited availability of the isotope, the challenging chemistry required to isolate Ac-225 from any co-produced isotopes, and the need for stable targeting systems with high radiolabeling yields. Results: Here we provide a review of available literature pertaining to these challenges in the Ac-225-radiopharmaceutical field and also provide insight into how performed and planned efforts at TRIUMF Canada's particle accelerator centre - aim to address these issues.